Pod Insights Masters of Scale 23andMe's Anne Wojcicki: Embrace the gatekeepers About this episode When Anne Wojcicki co-founded 23andMe, she carved out a brand-new space in personal health -- helping people become experts on their bodies right down to the DNA level. Then the federal regulators came calling. But instead of trying to outwit the FDA in the name of moving fast, Wojcicki made the call to work with regulators directly and collaboratively. Hear how she embraced "red tape" as a tool to scale — not swiftly, but sustainably.
Read a transcript of this interview at: https://mastersofscale.com/anne-wojcicki-how-and-why-to-embrace-gatekeepers/
Subscribe to the Masters of Scale weekly newsletter: https://mastersofscale.com/subscribe
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Transcript 0:01 Speaker 00 We've all spent money on something that seemed incredible but didn't live up to the hype. A kitchen gadget, a car. When it doesn't deliver, the disappointment is real. Marketers suffer from this too. Chasing metrics that look great but don't translate into revenue. LinkedIn calls that bull spend. Invest in what matters and reach the right buyers with LinkedIn Ads. You can target by company, industry, job title, and more. LinkedIn Ads also generates the highest ROAS of all major ad networks. Spend $250 on your first campaign on LinkedIn Ads and get a $250 credit for the next one. Just go to LinkedIn.com/Scale. That's LinkedIn.com/Scale. Terms and conditions apply.
0:49 Speaker 01 AI is full of possibilities. Enterprises run on realities. That's why Pega combines the world's most powerful AI with the governance, transparency, and control enterprises demand, so you can move faster, adapt faster, and scale AI with competence. All the power of AI, none of the uncertainty. Learn more at Pega.com/AI.
1:17 Speaker 02 Welcome to the Masters of Scale Movie Club.
1:27 Speaker 02 It's accepted knowledge that the 1994 Coen Brothers classic, "Hudsucker Proxy," is one of the best movies of all time, especially for entrepreneurs. Set in the utopian heyday of the late 1950s corporate boom, "Hudsucker Proxy" offers up a witty, wonky take on ambition, luck, and cutthroat competition that every founder can relate to. But there are many other nuggets of gold throughout the history of cinema, sometimes in movies you'd least suspect. Today, I want to look at three scenes in particular. They all come from very different movies, but each of them can tell us something about
2:12 Speaker 02 what we'll be examining on today's show. Something every startup can expect to face: gatekeepers. The first scene comes from Indiana Jones and the Raiders of the Lost Ark.
2:28 Speaker 02 Indy is racing through a busy Cairo market. Suddenly, the crowd parts, revealing a sword-wielding ruffian. He's clearly intent on cutting our hero to pieces, and he makes his intention clear with an elaborate display of sword swinging. Unperturbed, Indy nonchalantly pulls out his gun and shoots the guy. The lesson here: Sometimes, your best option is to cut through any gatekeepers that bar your way without hesitation. Our second movie is another Spielberg masterpiece: Jurassic Park.
3:07 Speaker 02 The scene is set in an industrial-sized kitchen with aisles of chromework surfaces. A velociraptor has cornered two children. They scurry around the reflective counters, trying to skirt around the dinosaur to freedom. The predator spots one of the children, cuddled in an alcove, and leaps to attack. But rather than being rewarded with a tasty human morsel, the dinosaur slams into cold metal. It was the little girl's reflection. Having outsmarted the dinosaur, she flees to safety. For many entrepreneurs, this is their natural approach to dealing with gatekeepers:
3:48 Speaker 02 Find a smart hack or ingenious ruse to get around the obstacle and keep up momentum. Our third scene comes from Monty Python and the Holy Grail.
4:02 Speaker 02 The knights have neared the end of their journey. All that stands between them and their destination, the castle of Arg, is the Bridge of Death and its guardian, the Bridgekeeper. The knights must answer five questions.
4:16 Speaker 03 It's three questions, sire.
4:18 Speaker 02 Three questions from the Bridgekeeper to pass. Lancelot answers first, and honestly, and is allowed to pass.
4:26 Speaker 03 You have to know these things when you are king, you know?
4:28 Speaker 02 But Robin and Galahad overthink their responses
4:31 Speaker 03 Blue! No, red!
4:33 Speaker 02 and are flung from the bridge.
4:40 Speaker 02 The learning here is that sometimes dealing directly and honestly with gatekeepers is the most prudent course of action. Of course, sometimes the red tape is so thick that dealing directly with gatekeepers, like regulators, vested interests, or other parties in control, can seem like far too much of a drag when you want to move fast and capture your market. Your instinct is to be more of an Indiana Jones than a Lancelot. But sometimes, it is actually beneficial to slow down and deal with all the red tape, especially if, in doing so, you'll be charting new territory.
5:24 Speaker 02 Because on the other side, you may find unfettered opportunity. I believe gatekeepers aren't an impediment that you should outwit, but an opportunity that you should embrace.
5:40 Speaker 04 You've got to have incredible talent at every position. It's like this huge push.
5:44 Speaker 03 There are fires burning when you're going home. Can you believe it?
5:47 Speaker 05 Such an idiot. And then you go back to, this is totally going to be amazing. There are so many easy wins. I have no idea what to do. Sorry, we made a mistake. But you have to time it right. Oops.
5:58 Speaker 06 Working out of a three-bedroom apartment. Stuff that just seems absolutely nutballs 10 years later, like, well, that's just how you do it. We haven't made it. Just how you do it.
6:10 Speaker 02 This is Masters of Scale.
6:16 Speaker 02 I'm Reid Hoffman, co-founder of LinkedIn, partner at Greylock, and your host. And I believe gatekeepers aren't an impediment that you should outwit, but an opportunity that you should embrace. Gatekeepers come in many forms, but there is one thing they all have in common: they bar the way ahead. And anything that prevents you from making constant, accelerating forward motion, particularly in the early stages of scale, is something you must avoid.
6:48 Speaker 02 There are many different approaches to tackling gatekeepers. You may opt for sheer force, battering your way through that gate, and consequences be damned. Or you may prefer the more subtle approach, biding your time until you see an opportunity to slip through. And of course, there's the method that appeals most to the entrepreneur in you. Finding an out-of-the-box route that takes you over, under, round, or through the gatekeeper in an audacious manner. But there are times when you will come up against a gatekeeper that is the immovable object to your unstoppable force.
7:34 Speaker 02 I wanted to talk to 23andMe founder Anne Wojcicki because her company is carving out exciting new opportunities in the sphere of genetic testing and health. But to get to this point, Anne faced a number of gatekeepers. She managed to work around these until she came up against one that was unavoidable: the FDA. She realized she had to put her scale ambitions on hold to work with them. In doing so, she has helped build a bridge toward an entire new growth industry. It is the combination of Anne's charisma, her belief in her mission, and her pragmatism that has led her to take 23andMe so far against the odds.
8:18 Speaker 02 Her journey has also taken grit, something Anne learned as a child on an outdoor ice rink in Palo Alto.
8:27 Speaker 07 I don't know what it was about ice skating. It was in that sense of like it was outdoors and you could be group or it was solitary. But I always found it like beautiful. You have the steam that kind of rises off in the mornings. Like I loved it.
8:41 Speaker 07 My parents did not get like it was expensive. There was a lot of sort of this pageantry of like your makeup, your hair, like which was obviously it's not a wojcicki trait.
8:52 Speaker 02 One thing that is very much a wojcicki trait is perseverance. Although her parents weren't keen on her passion for the rink, she kept going.
9:02 Speaker 07 I was really determined. Like, I don't really care that you don't like ice skating. Like, I'm gonna keep skating.
9:07 Speaker 02 Her parents were so against it, they refused to buy her skates. But that didn't make Anne put her passion on ice.
9:16 Speaker 07 So I had to win the skate-a-thon every year to get my skates. And so I'd walk around the neighborhood and collect money from my neighbors. And there'd be like a day-long skate-a-thon, how many laps do you do? But that's how I won my skates every year. Like, I didn't have a choice. It was like, I have to win it. I had a really great skating teacher who was a single mom, and I would babysit for her in exchange for skating lessons.
9:39 Speaker 02 It was a perseverance that was admirable, but also pushed against limits.
9:45 Speaker 07 I was kind of also known at the rink. Like, I often snuck in. And I remember them saying at some point, like, Anne, at some point, you need to pay for admissions.
9:52 Speaker 02 This is the kind of behavior a cute kid in a thick winter coat and skates can get away with. Anne has continued to be able to push limits while maintaining her charm into adulthood. When you next hear her speak, she's still talking about ice skating as a child, but she could just as easily be talking about her later experience with 23andMe.
10:16 Speaker 07 I loved it. It was one of the first areas where I really expressed, I'm gonna do this, whether you like it or not. And I just always figured out ways to keep doing it.
10:26 Speaker 02 True to her word, Anne stuck with the skates. She took them with her when she enrolled at Yale to study biology, as well as skate competitively and play on the ice hockey team.
10:39 Speaker 02 After she graduated in 1996, she started a career in healthcare investment. It combined her scientific training with another childhood obsession.
10:49 Speaker 07 I was always fascinated by investing, and I didn't know that you could get paid for it. In fourth grade, I remember calling up fidelity and saying, like, who picks your stocks? And I think the sales rep on the other side was kind of confused. But I was so interested in this process of, oh, someone is just analyzing companies all day. So, once I graduated college, I discovered you could get paid to do this, which was amazing to me. So, I spent 10 years investing in healthcare companies. I always loved hospitals. Like, I'm one of those people where I walk into a hospital and I take a deep sniff, and I'm like, I love it. Like, I just love, I love everything about hospitals.
11:25 Speaker 02 But it's often the things you love the most that you can see the most flaws in.
11:31 Speaker 07 I loved investing in healthcare and getting to know all the aspects of it and how these things work and the in-depth machinery. And as I got to know the space, I became more and more disillusioned that, like, wow, this is a really awful system. And that, in some ways, this system really takes advantage of sick people.
11:54 Speaker 02 Anne's professional career had been devoted to promoting this healthcare system, but as more cracks began to show, her priorities started to change.
12:04 Speaker 07 You start to realize the human component of margin expansion or a pricing scenario. I became more and more disturbed by how the healthcare system was. And at some point, I didn't feel like I could morally reconcile that I was investing in an industry that I didn't think was in the best interest for consumers.
12:23 Speaker 02 Anne took inspiration from grassroots efforts to put health in the hands of the people.
12:29 Speaker 07 I did get to know the HIV community really well in the late 90s, and I was impressed with how they advocated for themselves. And this is a community that didn't just say, I'm going to sit around and wait. They were a community that was very proactive.
12:45 Speaker 02 The healthcare system was a monolithic fortress manned by multiple, powerful gatekeepers. Getting it to change, though, was tough. Anne began thinking how advocate groups could amplify their voices and their ability to go up against those gatekeepers by using the internet.
13:08 Speaker 02 She found inspiration in her sister Susan's garage. It was at this time when Anne met her former husband Sergey Brin, who was working on a small startup with his partner Larry Page. Its name was Google.
13:22 Speaker 07 I happened to see Google starting in my sister's garage. And then I met people like Katerina Fake, who like sat me down and was like, this is the future of the web. People are going to connect. Web 2.0.
13:34 Speaker 02 Anne put together all these ideas and influences.
13:38 Speaker 07 And I kept thinking, I was like, healthcare is actually about all of us. And we should have this system where you can get your genetic information, which suddenly was accessible. And you can connect with each other, the way all these other social networks are starting to happen. And we're going to be able to like, why do I need the rest of the healthcare industry? Like, why do I need the hospitals? Why do I need the academics? We, like, we the people can actually stand up and self-report and we can crowdsource research.
14:07 Speaker 02 This was a problem Anne was passionate about solving. And so, when she thought she had a solution, she went all in. In 2006, Anne founded 23andMe with Linda Avi and Paul Cusenza. Its aim was to give people direct access to their genetic information and then use it to make decisions about their health.
14:30 Speaker 07 And so 23andMe really came out of this idea of social activism, like, based on the HIV community, that patients actually really want to come together. The social networking that was happening on the internet. And then last, the fact that there was actually a technology where you could affordably get access to your genetic information.
14:51 Speaker 02 23andMe would help patients get around the gatekeepers that barred the way to their health information.
14:59 Speaker 07 The consumer should actually have more control. They should have control of their medical records. They should have more, like, why do I have to go to a doctor every time I want a blood test? Like, I should just have more control. Within limits, but largely, we should have a better attitude about how we represent the consumer. That was the big picture. Like, I want to change that. And I want to have that trickle-down effect in all kinds of other aspects of healthcare.
15:26 Speaker 02 Now, patients would be able to identify diseases and conditions that they might be susceptible to, and then take measures to mitigate these risks. They would be able to look at an entire body of personalized knowledge and seek out precisely the right experts to help them. It would transform the current healthcare system that had first enthralled and then repelled Anne. 23andMe would provide easy-to-use genetic test kits to its customers. People would just need to provide a sample of saliva and return it. This would then be tested, and the results would flag any potential health issues that had been discovered.
16:08 Speaker 02 It was an unprecedented level of access to the very building blocks of life. Surely, everyone would leap at the chance. Well, if getting traction for ideas that promote the greater good were this simple, we'd already be living in a world without war, famine, or hate. Anne had fallen into this common trap. Her training experience had put her in the ideal place to see what was wrong and how to fix it. However, this same training experience meant it was too obvious for her. Her potential customers weren't even aware of the lock gates that 23andMe was offering them the keys to.
16:50 Speaker 07 We did no market research. Like, in some ways, it's like really cute how we launched this company. One of the things I also realized, like, a lot of great scientists are just really awful business people. I would talk to scientists, and they're like, "Wow, if you could launch a company like that, you would make so much money." You know, the thing that we realized in those early days is that most people have no idea why they'd ever want their genetic information.
17:15 Speaker 02 The term "market research" probably conjures up images of carefully-selected focus groups picking apart your product as you watch horrified from behind a two-way mirror. It's no wonder that many founders see it as an obstacle in their path to bringing their great idea into the world. But this is a narrow view because market research is about far more than letting a cross-section of your target audience prod and poke at your prototype. I like to call it "viability research" because it will tell you how much of an uphill struggle you will face in getting people to latch on to your product or service and all of its possibilities.
18:01 Speaker 02 Most ideas are iterative. They will improve upon a known product. You may need to educate your customers on small things, like which buttons to press. But the overall point of your product, well, that's obvious. Other developments can be far more transformative. Think of the Internet. It would transform society in unimaginable ways. However, it was still iterative in its development. You didn't need to understand all of the ramifications of instantaneous worldwide communication in order to send an email.
18:38 Speaker 02 However, something like 23andMe doesn't fit in either of these categories. People may have an understanding of genetics, but they had no idea how to use that information. No inkling of how having access to it could transform their entire way of thinking about health. 23andMe had huge potential power, but that power could only be realized in a future where systems and attitudes had shifted. So when 23andMe launched in 2007, it was met. With a shrug.
19:13 Speaker 07 Those early days, like we, we launched the company, we sold a thousand kits those first couple of days and then, and then we saw it trickle down to like 10 to 20 kits a day. It was so sad.
19:28 Speaker 02 But Anne didn't lose faith in her mission. This lack of understanding amongst her customers was another obstacle she was determined to overcome.
19:37 Speaker 07 I never once doubted that this was a viable business, but to me it was always that we have to take a different path. The path we approached of just putting out a scientifically really interesting product and we thought that there was like big consumer interest, that there had to be more education. So for me, it was like, I failed my customers more because I failed to properly educate them about the potential. So then we had to take a step back to say like, well, what are we going to do? One thing my marketing team will say is like, you need to take it from the weird to the wonderful.
20:12 Speaker 02 23andMe had enormous potential, but the concept behind it was too weird. Very few people could see the point of paying to have their genome analyzed. Anne needed to educate people about the benefits and then get them to sign up for 23andMe. Education doesn't mean putting together tiresome tutorials or laborious workshops. Think of it more in line with the filmmaking adage, show, don't tell. If you can put a product in your customers' hands, they may not get it immediately, but they can immediately start becoming familiar with it and then fall in love with it.
20:54 Speaker 02 For 23andMe, the trip from weird to wonderful was achieved by letting people learn about their ancestry.
21:02 Speaker 07 I think one thing that we were really clear about is that no one wants to sit around and talk about their disease all day. You know, I carry Hashimoto's, I have Hashimoto's, I take thyroid. Like, you would never want to do a podcast, like, just talking about my Hashimoto's, like, and all the interesting aspects of it. But if I came in and I was like, guess what? I found out I have ancestors from Thailand and West Africa in this. It's super interesting. And I've, like, met all these relatives, like, holy cow, we get stories all the time about that. So the ancestry side really opened up massive numbers of stories and explorations, this sense of identity. It's like, that's changed.
21:40 Speaker 02 This took genome testing from the weird to the wonderful, and also injected an urgency for people to share. Note how helping people explore their genetic ancestry wasn't directly part of Anne's mission, but it was additive to giving people more power over their medical histories.
22:02 Speaker 07 People always ask, like, are you a biotech community? Are you a science community? What are you? And I said, we look at genetics holistically. Your genetic is just the digital manifestation of you, and you are really interesting.
22:15 Speaker 02 You sometimes need to take oblique, yet complementary, approaches to reach your goal. This helps you gain scale rapidly. It prompts you to diversify. It can also be a lifeline if you hit any unexpected and powerful blocks, like the powerful gatekeeper Anne was about to run into. We'll hear about that after the break.
22:46 Speaker 00 We all know the disappointment that comes when a grand gesture falls flat, something that seemed impressive in the moment but didn't deliver the results you expected. Marketing budgets too often fall into that trap, aiming for big impressions, big reach, but without the revenue to back it. LinkedIn has a name for it: Bullspend. LinkedIn Ads generate the highest ROAS of all major ad networks. They target by company, industry, job title, and more. Spend $250 on your first campaign on LinkedIn Ads and get a $250 credit for the next one. Just go to LinkedIn.com/Scale. That's LinkedIn.com/Scale. Terms and conditions apply.
23:30 Speaker 00 When you've built substantial wealth through your business, it's often tied up in a single equity position. The upside is real, but so is the risk, and knowing when to act isn't always obvious. Creative Planning works with business owners to build a strategy around concentrated equity, when to diversify, how to manage tax risk, and how to protect what you've spent years building. Creative Planning, where wealth works together. Learn more at creativeplanning.com/mastersofscale. Every business hits the same wall the moment your business outgrows the systems that got you here. Spreadsheets everywhere, five different logins, data scattered across entities that don't even talk to each other. If your finance team spends more time
24:15 Speaker 00 finding data than using it, that's when you need the Intuit ERP. Intuit Enterprise Suite is the AI-native ERP solution that's powerful, painless, and proven, built for businesses scaling fast without the complexity that usually comes with it. From the makers of QuickBooks, learn more at intuit.com/erp.
24:41 Speaker 02 Before the break, we heard how Anne and her team took 23andMe from alien concept to must-try marvel. In 2008, Time Magazine named 23andMe's personal genome test kit Invention of the Year. People were excited about exploring their ancestry, and they were being introduced to the concept of using genome testing to gain more information about their health. But although consumers were coming around to 23andMe, there was a group that was proving tough to convince: doctors.
25:16 Speaker 07 We're direct-to-consumer, and I think that that is one of the biggest controversies about the company, is that we don't go through doctors. So, most of your health information today, access is controlled by physicians. But if you look at the history of medicine, things like pregnancy tests, it was seen as highly controversial at the time whether or not people should get direct access to their pregnancy results.
25:39 Speaker 02 Doctors have been the established gatekeepers. It was a setup that had until now remained unquestioned since the days of Hippocrates.
25:49 Speaker 07 So for physicians, they're used to having the information come first to them. And then they're used to deciding whether or not you should have information. So it was sort of shocking that people were walking in and saying, look at all these things I learned about myself. Like, what do you think? For me, it wasn't shocking because I remember so well when I was investing in WebMD and physicians had a very similar opinion. It was like, wait a minute. I'm the one who would tell you all the different potential diagnoses.
26:15 Speaker 02 There was another problem. 23andMe's focus on encouraging people to take preventative measures.
26:22 Speaker 07 At one meeting, a doctor stood up and he said, look, the biggest problem with 23andMe is you generate non-billable questions. This is like where I have the empathy for the physicians because a lot of what we do is we bring up risks. And risks are not something that's usually well-covered in the healthcare system. Doctors are really trained to treat the disease. But thinking about prevention, in some ways, like that falls on you. We're playing in a world that's kind of outside of traditional medicine.
27:00 Speaker 02 23andMe was facing a systematic and cultural block to their business. And if doctors wouldn't come aboard, then consumers might be turned off. It's an issue that the company is still dealing with.
27:15 Speaker 07 So I recognize like it was more of a transition. And we took the direct-to-consumer approach, frankly, because it's a much more scalable approach. Like, it's what I've learned in Silicon Valley, like consumers can drive behavior change. I was never going to be able to afford to have a physician education campaign. So we created all kinds of support materials for physicians. We wanted to make sure they understood what we were doing and it was scientifically valid. But the medical community definitely has been slow to adopt genetics.
27:45 Speaker 02 However, there was one gatekeeper even more challenging than the medical community, the Food and Drug Administration. 23andMe was offering raw genetic info, ancestry, and reports on genetic diseases.
28:00 Speaker 02 The ancestry aspect was the wonderful that was helping people understand the weird. However, in 2010, the FDA told 23andMe that it had classified genetic tests as medical devices. This meant 23andMe would need federal approval to market them.
28:20 Speaker 07 The FDA story is always really interesting to people. I do this class every year at Stanford Business School, and they survey the students. And they're like, did 23andMe get their warning letter because of Silicon Valley arrogance or just like totally ineptitude? And overwhelmingly, they vote on Silicon Valley arrogance. And I always, I kind of love it.
28:40 Speaker 02 I can't blame them for voting that way. Silicon Valley, unfortunately, has become a byword for arrogance. And I think it's unfortunately justified. But I also think it's a shame, because putting up a spirited fight for a product you believe in isn't arrogant in itself. Disruption has become a negative term. But the flip side is that it is disrupting vested interests and gatekeepers and making the world better for everyone. I want to get back to that sense of disruption. It's not that Anne and her team had arrogantly decided to ignore the FDA.
29:20 Speaker 02 In fact, right from the start, they had been speaking with both state and federal regulators.
29:26 Speaker 07 We got multiple different state-level warning letters. Like, we had a cease and desist from the state of California. We'd gotten letters from New York.
29:36 Speaker 02 Okay, when I said that Anne and her team hadn't arrogantly decided to ignore the regulators, this wasn't exactly true. They'd had multiple run-ins with state-level regulators. And each time, they found ingenious workarounds that kept 23andMe's business in full swing. For example, collecting saliva to test for DNA.
30:00 Speaker 07 We had this issue where you couldn't legally spit in the state of New York, but you could spit on like the George Washington Bridge. And so, I remember like, that was kind of our workaround there. We were kind of clever at coming up with like, okay, let's figure out how we can make this work.
30:17 Speaker 02 Though I would say, it was more playful than arrogant.
30:24 Speaker 07 By the time of our warning letter from the FDA, we were kind of used to controversy and used to also knowing how to deal with it.
30:32 Speaker 02 In 2013, the FDA sent a cease and desist letter to 23andMe. Anne was going to treat it like all of their previous run-ins with the FDA.
30:43 Speaker 07 So when we got it, my first reaction was like, oh, it's not a big deal. You know, this is manageable, like, no one panic, it's fine.
30:51 Speaker 02 However, this time, it was a big deal. The FDA claimed that because 23andMe was offering medical advice, it was a healthcare product. It was a clash that had been brewing since 23andMe had launched.
31:07 Speaker 07 But by Monday morning, when the FDA published it and press came out and some of that original team from, you know, FDA advisors had called and they're like, this is no joke. It was the first time in my experience where the problem was not solvable. I really had to shift mentality.
31:26 Speaker 02 At first, Anne took the classic approach of any entrepreneur. She tried to find the smart workaround that would let her get back to scaling as quickly as possible.
31:37 Speaker 07 I was like, I don't know what the solution is. I called around, spent weeks in my pajamas, like, just like calling people and getting advice.
31:46 Speaker 02 With her back against the wall, Anne's first instinct was to do what many other impassioned founders have done in the face of gatekeepers: fight.
31:55 Speaker 07 My first instinct was, I represent the consumer and the consumer has a First Amendment argument here. It's their information and they're just interpreting their information.
32:04 Speaker 02 But then Anne had a revelation sparked by an encounter with one of the very regulators she was preparing to do battle with.
32:13 Speaker 07 I had one very wise regulator who asked me, she was like, well, what do you want to do? Do you want to sell this company in two years? And if you want to do that, this is your strategy. But if you really want to change healthcare, you just sit down and you work with the FDA and you do the hard work. And it's going to take you years. And you got to be ready. At the end of those years, you will have really changed society, but you got to know that you're committed to doing that.
32:47 Speaker 07 And I said, I was like, you know, I'm like 30, whatever, like not going anywhere. Like, what else do I have to do? I'm committed.
32:54 Speaker 02 We tend to see gatekeepers as obstacles that we need to circumvent. But a gatekeeper doesn't just block the way, they can also open it for us. Years of working through and around various run ins with state and federal regulators meant Anne had very good contacts with these various gatekeepers. Enough to have kept from being totally stopped in her tracks until now. But what if she hadn't cultivated those contacts? Knowing who to talk to is important when dealing with gatekeepers. It's a problem Spotify founder Daniel Ek ran into when he was trying to convince the music industry to get on board.
33:36 Speaker 05 You know, I slept in these like $30 a night motels where the wallpaper falls down on you and there's all sorts of things in the bathroom that you don't want to know what it is running around. It wasn't a very nice time. I did sleep outside of the conference room for a few nights, waiting for an executive to turn up at one point. The reason why that happened was that, you know, the way the music industry works is there's certain things that the local teams can take a decision on. There's certain things that the European or international team can take decision on and there's certain things that people at the global headquarters need to take a decision on. This was one of those hairy things where no one really knew where we would fall under.
34:21 Speaker 05 You know, I never worked on trying to sell anything to a large company before. So, understanding who's who in the hierarchy and who influences a decision, who the stakeholder is, and it took me a good bunch of time before I realized who I was even talking to in the room.
34:37 Speaker 02 It was a long process that put the brakes on Spotify's early expansion. But by taking the time to learn the ways of the music industry gatekeepers, Daniel was setting Spotify up to lead the way in music streaming. This is a strategy Anne followed with the FDA.
34:55 Speaker 07 If you can change regulators and you can help them understand and you can prove out, then you're going to have a much bigger impact on society.
35:04 Speaker 02 Anne came around to seeing the run in with the FDA as an opportunity, but it was a long task.
35:11 Speaker 07 And I have to say, it was painful. There were some early days that were awful, that were just really painful.
35:18 Speaker 02 It was a distraction from the mission, the kind of distraction that would raise the hackles of any founder.
35:24 Speaker 07 Trying to get a nimble tech system where you're just constantly used to iterating and calling and doing all this stuff, to suddenly saying, no, you have to do this validation work.
35:36 Speaker 02 But if they could get through to the other side, they would be first and they would have a clear head start.
35:42 Speaker 07 Everyone in this building believes in the potential of the consumer and the potential of this direct to consumer pathway. One of my lawyers used to say, she's like, Anne, you're on the right side of history. And it was almost like law and the beauty of a case and a beautiful position and story. It's a matter of what is the data that I have to put together that's going to help us reach that endpoint, but it's going to take years.
36:09 Speaker 02 Anne could have gone in guns blazing and fought the FDA, but instead, they decided to pull back and slow down iteration. Usually, this is the last thing a founder should do. And I think this is where a lot of the bad vibes around disruption come from. Disruption doesn't need to mean destruction. Your disruptive wave may initially set all of the boats on a lake bobbing up and down frantically, and it could upturn them, but it can also raise the water level higher for everyone. But some founders can lose sight of this. Rather than believing in their wider mission, like Anne does, they fall into the trap of believing
36:54 Speaker 02 solely in their narrow product. But in 23andMe's case, no one else was going to grab market share. The FDA was a hard ceiling that someone would need to break through.
37:08 Speaker 02 Although working with the FDA would be slow, it would build trust that would allow 23andMe and those who followed it to grow rapidly in the long term.
37:18 Speaker 07 The FDA sees a lot, and there's a lot of bad actors out there. And so I have a lot of respect for them. Having gotten to know them now better, like, they have a tough job. Like, it is a tough job. You're constantly dealing with people who are trying to trick you. And so it is, like, it's our responsibility to show that what you're doing is safe, that people can understand it. And the more you show it, the more comfortable they get with it. The more we can establish, like, hey, consumers in all broad swathes of the area of healthcare can understand this information, the easier it will be.
37:51 Speaker 02 By working with the FDA, Anne has made it easier for other firms entering the field, for the FDA to understand their aims, and for consumers to get on board with 23andMe's weird and wonderful mission.
38:08 Speaker 07 I think the trust element is one of the biggest, and in part because, you know, we are a company that works with really sensitive information. Like, I have your genetic blueprint, and I ask you lots of questions about you. And then I want to do research. I want to make discoveries, like, on depression and allergies and asthma and fun characteristics. But we have a lot of really sensitive information on customers, and we have to prove that we're, like, responsible every day and that we're making good decisions. And our customers trust us on this. And so because we have this research mission, the only way we will ever understand the human genome
38:51 Speaker 07 and the only way that we will all collectively benefit from the human genome is if we trust.
38:57 Speaker 02 Trust won. The floodgates are open for wave after wave of new possibilities.
39:04 Speaker 07 Once we got to that first million, we learned that there is a really natural viral component to it, that people want to learn about their ancestry. They want to connect with friends and family. I look back on the decision that we made pre FDA to say, get to a million people. It's the most important thing for us to do because you're disruptive. Like, I don't know how it will happen, but I know it will catch fire.
39:30 Speaker 02 Because Anne, Anne 23 and Me, took the time to work with the FDA, they helped set a roadmap for the wider industry, although there are still limitations they face.
39:41 Speaker 07 I have to say, like, I'm really proud today. Like, we don't have our full product back, and we suffer lots of pain. And I can see other companies doing things that I wish we could do. But fundamentally, I feel like I'm speaking the language of regulators and scientists in that I'm proving out my position with data, and we're succeeding.
40:02 Speaker 02 They can now focus on all the exciting possibilities ahead.
40:06 Speaker 07 A lot of those things come with scale. Health is one of those things. People are still figuring out how to use this information. And like, what does it mean for me to like, step up? If I'm higher risk for, you know, type 2 diabetes, like, what do I do? And there's not a huge support system yet. And that's one of the things I think Silicon Valley will have more and more of a role to step up in. And so I see the next decade, in some ways, as like, driving a lot of the viral connections. There's going to be a different healthcare world than the world that we know today. And the world we know today, that is predicated on physicians and hospitals and in-person visits. There's going to be an entire healthcare world that's predicated on your phone.
40:51 Speaker 02 It's a grand vision that will not be easy to make a reality. But it would have been impossible if Anne hadn't taken the time to work with the gatekeepers. I'm Reid Hoffman. Thank you for listening.
41:09 Speaker 02 Humans will never be more intelligent than AI. There's going to be two types of companies. Those who are great at AI, and those that went out of business because they weren't.
41:17 Speaker 01 How do we build a future that is human-centered? I'm Rana Elkhauyubi, and on my podcast, Pioneers of AI.
41:27 Speaker 05 AI, we answer that question and so many more. As an AI scientist, entrepreneur and investor, I know what it takes to build AI that works for everyone. Every week, I sit down with the pioneers shaping our future, and we take you behind the scenes of the AI that's transforming our lives. Find pioneers of AI wherever you tune in.
41:51 Speaker 03 We all know the really prominent technology podcasts out there, but they're not actually helping the majority of people understand this space. With Future Proof, that's what we want to do. We want to talk to everyone from the top AI labs to the real builders, the people who are rolling up their sleeves, building this technology on a day-to-day basis. I'm Reid Albergati. I've been covering technology for more than a decade. If you want to really learn, whether you're in the tech industry, adjacent to it, or just curious about it, subscribe to Semaphore's Future Proof wherever you get your podcasts or watch it on YouTube.
42:24 Speaker 02 Hey, listeners, Bob here. If you listen to Rapid Response on Masters of Scale, you may be missing half the show because every Friday, we release a second Rapid Response exclusively in the Rapid Response feed. The guests and topics are just as compelling and timely, from Ford CEO to NASA's administrator to the lessons from the devil wears Prada. It takes about 10 seconds to find. Just search Rapid Response wherever you listen to podcasts and hit follow to make sure you never miss an episode. I hope to see you there.
43:02 Speaker 02 Masters of Scale is a Wait What original. The show is recorded on site in California and produced at the studio inside SY Partners in New York. Our executive producers are June Cohen and Darren Triff. Our producers are Chris MacLeod, Adam Skuse, Jenny Cataldo, Jordan MacLeod, and Ben Manila. Our supervising producer is Jay Punjabi. Original music by Alison Leighton Brown. Sound design, mixing and mastering by Brian Pugh. Special thanks to Chris Ye, Alisa Schreiber, David Sanford, Saida Sapieva, Kristina Gonzalez and Sarah Sandman. Visit mastersofscale.com to find the transcript for this episode and be sure to subscribe to our email newsletter. You
43:58 Speaker 02 can
Previous The Big Pivot w/Slack's Stewart Butterfield Next Bonus: Recharge your brain with a Meditative Story by Arianna Huffington Page updated October 24, 2026 · transcript and summary are machine-generated